Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 clinical study of COVID-19 vaccine(Coronavirus vaccine)

Trial Profile

A Phase 1 clinical study of COVID-19 vaccine(Coronavirus vaccine)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2020

At a glance

  • Drugs Coronavirus vaccine (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 30 Mar 2020 According to an Johnson & Johnson media release, the company plans to initiate this trial latest by September 2020 and clinical data on safety and efficacy is expected to be available by the end of the year.
    • 13 Mar 2020 According to an Johnson & Johnson media release, the company plans to initiate this trial by the end of the 2020.
    • 17 Feb 2020 New trial record

Trial Overview

Purpose

This study will evaluate the COVID-19 vaccine(Coronavirus vaccine).

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention -

Subjects

  • Subject Type volunteers
  • Sex male & female

Trial Details

Organisations

  • Sponsors Johnson & Johnson
  • Affiliations Janssen Pharmaceuticals; Johnson & Johnson

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I
  • Location USA
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
Coronavirus vaccinePrimary Drug Parenteral
-

Coronavirus-vaccine

Trial Centres

Centres

Centre Name Location Trial Centre Country
Johnson & Johnson Pharmaceutical Services
-
-

Trial History

Event Date Event Type Comment
30 Mar 2020 Other trial event According to an Johnson & Johnson media release, the company plans to initiate this trial latest by September 2020 and clinical data on safety and efficacy is expected to be available by the end of the year. Updated 02 Apr 2020
13 Mar 2020 Other trial event According to an Johnson & Johnson media release, the company plans to initiate this trial by the end of the 2020. Updated 18 Mar 2020
17 Feb 2020 New trial record New trial record Updated 17 Feb 2020
11 Feb 2020 Other trial event According to an Johnson & Johnson media release, BARDA will provide funding to support accelerated development of a vaccine candidate into phase I studies. Updated 17 Feb 2020
11 Feb 2020 Other trial event According to an Johnson & Johnson media release, the company announced that its Janssen Pharmaceutical Companies enters into a collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to further expedite its new coronavirus vaccine programme. Under the terms of the agreement, Janssen and BARDA will both contribute to the research and development costs and mobilise resources to rapidly advance the initial stages of Janssen's COVID-19 vaccine development programme. Updated 17 Feb 2020

References

  1. Johnson Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine. Media-Rel 2020;.

    Media Release
  2. Johnson Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development. Media-Rel 2020;.

    Media Release
  3. Johnson Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use. Media-Rel 2020;.

    Media Release
Back to top